Please assess the completion status of the following clinical trial:

Trial Title: Canakinumab for Treatment of Adult-onset Still's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written and signed consent from the participant to take part in the study~2. Men and women aged ≥ 18 years and ≤ 75 years~3. Fulfilment of AOSD classification criteria (according to Yamaguchi et al, J. Rheumatology, 1992)~4. Disease activity based on Disease Activity Score 28 (DAS28) of ≥3.2 at screening~5. At least 4 painful and 4 swollen joints at screening and baseline (of the 28 joints according to DAS28)~6. If undergoing treatment with non-steroidal anti-inflammatory drugs (NSAIDs), stable dose for at least 4 weeks prior to randomisation~7. If undergoing treatment with glucocorticoids, stable dose of ≤10 milligrams per day (mg/day) (prednisolone or equivalent) for at least 4 weeks prior to randomisation~8. If undergoing treatment with conventional disease-modifying anti-rheumatic drugs (DMARD), stable dose for at least 3 months prior to randomisation~9. Normalisation period for biological DMARDS (anakinra 1 week, etanercept 1 month, adalimumab and certolizumab 2 months, infliximab, golimumab, abatacept and tocilizumab 3 months, rituximab 9 months, canakinumab 6 months) prior to randomisation~10. In participants of reproductive age, use of an effective method of contraception as well as negative pregnancy test prior to the study commencing.~Exclusion Criteria:~1. Previous treatment with the study drug with repeated administration of canakinumab~2. Intraarticular or intravenous administration of glucocorticoids within 4 weeks prior to the baseline or use of narcotic analgesics except for analgesics permitted within the framework of the investigation (codeine and tramadol)~3. Presence of another, serious chronic-inflammatory disease~4. Positive hepatitis B antigen (HBsAg), hepatitis C antibodies and/or human immunodeficiency virus (HIV) antibodies.~5. Presence of a relevant, active infection or other diseases, which entail a tendency towards infection~6. Positive screening for latent tuberculosis, in accordance with usual local practice~7. Raised liver count (raised bilirubin; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3-fold the normal range)~8. Serum-creatinine concentration \>1.5 milligrams per deciliter (mg/dL)~9. Inadequate haematological findings (hemoglobin \[Hb\] ≤ 10 grams per deciliter (g/dL), neutrophils ≤2,500/microliter (µl) and thrombocytes ≤100,000/µl)~10. Simultaneous participation in any other interventional clinical study within the last 30 days preceding the commencement of the study~11. History of neoplasia with the exception of a curatively treated non-melanoma skin tumour or carcinoma of the cervix treated in situ without any indication of recurrence within the last 10 years~12. Relevant cardiac or pulmonary disorders~13. Severe intercurrent neurological or psychiatric disorders~14. Macrophage activation syndrome (MAS) as part of previous treatment with IL-1 blockade (e.g. anakinra, rilonacept)~15. Vaccination with a live vaccine within 3 months before the baseline~16. Alcohol or drug abuse in the past 12 months~17. ≥400 milliliter (mL) donation of blood or loss up to 8 weeks before the baseline~18. Pregnancy or breast-feeding~19. Commitment of the patient to an institution at the direction of an authority or court

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Canakinumab (Type: EXPERIMENTAL): Participants received canakinumab 4 mg/kg up to a maximum of 300 mg subcutaneous (SC) injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score \> 1.2 at Week 12) continued to receive same dose of canakinumab in Part II for Weeks 12, 16, and 20. Participants who had remission (change in DAS score \> 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo, SC injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score \> 1.2 at Week 12) continued to receive placebo at Weeks 12, 16, and 20. Non-responders (who had change in DAS score ≤ 1.2) were unblinded to receive canakinumab 4 mg/kg (up to 300 mg maximum), SC injection, at Weeks 12, 16, and 20. Participants who had remission (change in DAS score \> 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27.

Based on this trial design, predict the completion outcome and termination type (if applicable).